Company Overview and News

 
Ramelius Resources exceeds March quarter guidance on way to 200,000 ounces in 2018

2018-04-09 proactiveinvestors.com.au
The company’s production of 58,671 ounces in the March 2018 quarter from its three projects in Western Australia was a record.
Upvote Downvote

 
S&P/ASX 200 spikes 100 points on the open, but up 1% in afternoon trading

2018-02-07 proactiveinvestors.com.au
S&P/ASX 200 (XJO) spiked to a high of 5938 points on the open, up from the previous day’s close of 5803 points.
Upvote Downvote

1
Gold miners steady on quarterly results

2018-01-30 businessnews.com.au
Shares in gold miners Perseus Mining, Ramelius Resources and Evolution Mining have remained steady today following the release of the companies quarterly reports.
Upvote Downvote

 
Evolution Mining posts Q4 report, gold down 14.4%

2018-01-30 australianmining.com.au
Evolution Mining has posted its fourth quarter 2017 operational report, and overall gold output fell by 14.4 per cent, when compared with third quarter results, to 186,488 ounces (oz).
Upvote Downvote

1
Monax Mining will reveal gold resource within weeks

2018-01-04 proactiveinvestors.com.au
Monax Mining Limited (ASX:MOX) is preparing a resource estimate for its Western Queen Gold Project in Western Australia.
Upvote Downvote

 
Genesis Minerals commences drilling at Barimaia gold project in WA

2017-12-07 australianmining.com.au
A 2500-metre reverse circulation drilling program has been launched by Genesis Minerals at the Barimaia gold project in Western Australia.
Upvote Downvote

 
Gold industry launch tourism project

2017-10-10 perthnow.com.au
THE gold industry has subtly heaped more pressure on the McGowan Government to drop its royalty hike, launching a new tourism project designed to showcase the history and importance of gold to WA.
Upvote Downvote

 
CSIRO identifies growth opportunities for oil and gas sector

2017-10-04 australianmining.com.au
Rio Tinto is a step closer to its goal of having a network of driverless trains in the Pilbara after undertaking the first fully autonomous rail journey at the Western Australian iron ore operations.
Upvote Downvote

 
Mortgage arrears hit five-year high

2017-09-18 perthnow.com.au
THE Australian market looks set to open slightly higher after Wall Street made strong gains with the Dow closing at its fifth consecutive record high and the S&P 500 its second. At 0700 AEST on Tuesday, the share price futures index was up six points, or 0.1 per cent, at 5,726.
Upvote Downvote

 
Evolution Mining says goodbye to Edna May gold mine

2017-09-18 theage.com.au
Australia's second biggest gold miner, Evolution Mining, has managed to ride out a hike in mining royalties to strike a complicated deal to sell the Edna May gold mine in Western Australia for up to $90 million.
Upvote Downvote

 
ASX climbs 0.4pc as Wall St records inspire investors

2017-09-18 theage.com.au
Strong appetite for the banks on Monday bolstered the ASX, with investors largely ignoring the latest North Korean missile test and taking their lead from a record-breaking Friday night on Wall Street.
Upvote Downvote

 
ASX climbs 0.4pc as Wall St records inspire investors

2017-09-18 smh.com.au
Strong appetite for the banks on Monday bolstered the ASX, with investors largely ignoring the latest North Korean missile test and taking their lead from a record-breaking Friday night on Wall Street.
Upvote Downvote

 
Evolution Mining says goodbye to Edna May gold mine

2017-09-18 smh.com.au
Australia's second biggest gold miner, Evolution Mining, has managed to ride out a hike in mining royalties to strike a complicated deal to sell the Edna May gold mine in Western Australia for up to $90 million.
Upvote Downvote

 
Ramelius buys Evolution's Edna May for $90m

2017-09-18 businessnews.com.au
Ramelius Resources is set to become a 200,000 ounce per annum gold producer after acquiring Evolution Mining’s Edna May operation near Merredin for $90 million in cash and shares.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...